

REMARKS

This Amendment Reply is in response to the Office Action dated October 4, 2007 and further to the brief discussion on October 8, 2007 with Examiner Kaufman. During this discussion the Examiner was advised that an amendment after final was to be submitted wherein the claims were to be amended to overcome the objections and rejections raised in the Office Action.

Essentially, as discussed the previous claims are rewritten in order to exclude TLR9/CD40 agonist combinations and methods of use of such combinations. This subject matter is to be pursued in a continuation application. In addition, because of the exclusion of TLR9 agonist/CD40 agonist combinations from the claims the 4-1BB agonist/TLR agonist combinations are claimed separately from the CD40 agonist/TLR agonist combinations. Also, the informalities in the prior claims and the indefiniteness issues are overcome. In particular, the current independent and dependent claims do not recite "of any" and the formal issues noted in the paragraph on the top of page 2 of the Final Office Action are moot in view of the current claims which lack such informalities.

Otherwise, Applicants respectfully believe that the claims are identical to the prior claims.

The prior art issues are not addressed herein as they are moot in view of the present amendments. Applicants confirmed in the recent telephonic discussion with Examiner Kaufman that the prior art rejection was only relevant to the claims embracing TLR9 agonist/CD40 agonist combinations. As noted above, and as can be seen from the current claims, such combinations are no longer claimed as this subject matter is to be pursued in a continuation application.

Amendment and Response

Serial No.: 10/748,010

Confirmation No.: 7654

Filed: 30 December 2003

For: IMMUNOSTIMULATORY COMBINATIONS

It is respectfully submitted therefore that the current pending claims 108-184 are in condition for allowance and notification to that effect is respectfully requested. However, if any issues remain outstanding upon consideration of this Reply The Examiner is respectfully requested to contact the undersigned so that grant of this application may be expedited.

It is believed that no fees are due with this submission. In the event fees are due, the Commissioner is hereby authorized to charge or credit any such variance or credit any overpayment to the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Date: **November 1, 2007**

By:



Robin L. Teskin

Reg. No. 35,030

Hunton & Williams LLP
1900 K Street, N.W.
Suite 1200
Washington, D.C. 20006-1109
Phone: (202) 955-1500
Fax: (202) 778-2201